| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President | President | Director
3 companies
Charles S. Ryan is President at QNCX, with reported holdings spanning 3 companies. Charles S. Ryan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.2M at current prices.
Charles S. Ryan's largest disclosed position is in QNCX as President, worth about $4.1M. Net of sales, the QNCX filings show accumulation of 48,387 shares.
Charles S. Ryan has 22 Form 4 filings on record from April 2015 to January 2026, across 4 companies: President at IRulya Therapeutics (IRLA), 2026; President at Quince Therapeutics (QNCX), 2023–2025; Director at Bnb Plus (BNBX), 2015–2019, and 1 more.
The 40 reported transactions were 24 option or other derivative awards, 8 dispositions back to the company, 5 open-market purchases and 3 stock awards.
Counted by filing, the open-market trades come to 3 purchases worth about $106K and no sales.
The largest open-market purchase was 200,000 shares of BRTX at an average $0.25 on May 8, 2015, about $50K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2024 | QNCX Quince Therapeutics, Inc. | President | Buy | 48,387 | $0.65 | $31,451.55 | +65.3% | +186.9% | +167.2% | |
| Dec 7, 2015 | BRTX Biorestorative Therapies, Inc. | Director | Buy | 6,250 | $4.00 | $25,000.00 | +62.5% | - | - | |
| May 8, 2015 | BRTX Biorestorative Therapies, Inc. | Director | Buy | 200,000 | $0.25 | $50,000.00 | New | - | - |